Bottom line
How much do PBE and RYOIX overlap?
37% of their top holdings overlap by weight. 10 securities appear in both funds' top 25, making up 41.4% of PBE's assets and 28.1% of RYOIX's. They share a meaningful core but differ in the rest of the portfolio.
RYOIX holds far more positions (74 vs 33), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings PBE and RYOIX have in common
| Holding | % of PBE | % of RYOIX | Overlap |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 5.47% | 2.93% | 2.93% |
| Amgen Inc. | 5.22% | 5.05% | 5.05% |
| Vertex Pharmaceuticals Inc. | 4.99% | 4.32% | 4.32% |
| Biogen Inc. | 4.79% | 2.13% | 2.13% |
| Gilead Sciences, Inc. | 4.43% | 4.49% | 4.43% |
| United Therapeutics Corp. | 4.08% | 1.72% | 1.72% |
| Illumina, Inc. | 3.51% | 1.94% | 1.94% |
| Alnylam Pharmaceuticals, Inc. | 3.17% | 2.36% | 2.36% |
| Incyte Corp. | 3.06% | 1.62% | 1.62% |
| Neurocrine Biosciences, Inc. | 2.66% | 1.52% | 1.52% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in PBE
- Invesco Private Prime Fund — 12.89%
- CareDx, Inc. — 5.04%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Bio-Techne Corp. — 3.73%
- Protagonist Therapeutics, Inc. — 3.40%
- Vericel Corp. — 3.27%
- Repligen Corp. — 3.04%
- Acadia Pharmaceuticals Inc. — 3.02%
- Halozyme Therapeutics, Inc. — 2.98%
- Qiagen N.V. — 2.89%
- BioMarin Pharmaceutical Inc. — 2.82%
- Exelixis, Inc. — 2.64%
- BioCryst Pharmaceuticals, Inc. — 2.63%
- Veracyte, Inc. — 2.60%
Only in RYOIX
- Abbvie Inc — 8.17%
- Revolution Medicines Inc — 2.48%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Natera Inc — 2.12%
- Royalty Pharma Plc — 2.01%
- Insmed Inc — 1.79%
- Guardant Health Inc — 1.72%
- Roivant Sciences Ltd — 1.66%
- Viatris Inc — 1.55%
- Argenx Se — 1.48%
- Jazz Pharmaceuticals Plc — 1.42%
- Bridgebio Pharma Inc — 1.38%
- Ionis Pharmaceuticals Inc — 1.35%
- Cytokinetics Inc — 1.35%
Asset mix
| Asset type | PBE | RYOIX |
|---|---|---|
| Stocks | 100.1% | 99.6% |
| Cash & short-term funds | 17.9% | 0.6% |
| Repurchase agreements | — | 0.6% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Country mix
| Country | PBE | RYOIX |
|---|---|---|
| US | 108.6% | 85.8% |
| GB | 4.9% | 3.2% |
| CH | — | 3.3% |
| NL | 2.9% | 1.5% |
| IE | — | 2.7% |
| BM | — | 1.7% |
| KY | 1.6% | 0.5% |
| DE | — | 1.2% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / Jun 30, 2026)
Check another pair
FAQ
How much do PBE and RYOIX overlap?
What stocks do PBE and RYOIX have in common?
Should I own both PBE and RYOIX?
Which holds more stocks, PBE or RYOIX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.